二季度业绩逐步加速，净利润创单季度历史新高 恒立液压(601100) 证券研究报告 工程机械 / 公司点评 / 2025.08.26 核心观点 | 盈利预测 | | --- | 投资评级:增持(维持) | 基本数据 | 2025-08-25 | | --- | --- | | 收盘价(元) | 83.80 | | 流通股本(亿股) | 13.41 | | 每股净资产(元) | 12.22 | | 总股本(亿股) | 13.41 | 最近 12 月市场表现 -5% 17% 39% 61% 83% 104% 恒立液压 沪深300 分析师 佘炜超 SAC 证书编号：S0160522080002 shewc@ctsec.com 分析师 张豪杰 SAC 证书编号：S0160522090002 zhanghj01@ctsec.com 相关报告 1. 《液压泵阀份额持续提升，线性驱动新品 逐步放量》 2025-04-29 2. 《三季度业绩稳健增长，非标油缸及泵阀 保持较快增长》 2024-10-29 3. 《非标油缸及泵阀较快增长，二季度业绩 超预期》 2024-08-27 | [币种Table_FinchinaSimp ...

深化"AI+车"技术应用，传统与科技双线并行 千里科技(601777) 证券研究报告 摩托车及其他 / 公司点评 / 2025.08.26 投资评级:增持(维持) | 基本数据 | 2025-08-25 | | --- | --- | | 收盘价(元) | 10.64 | | 流通股本(亿股) | 45.21 | | 每股净资产(元) | 2.33 | | 总股本(亿股) | 45.21 | 最近 12 月市场表现 -5% 34% 74% 113% 153% 192% 千里科技 沪深300 分析师 佘炜超 SAC 证书编号：S0160522080002 shewc@ctsec.com 分析师 谢铭 SAC 证书编号：S0160523010001 xieming@ctsec.com 分析师 孟欣 SAC 证书编号：S0160523090002 mengxin@ctsec.com 相关报告 1. 《老树新花，千里马拥抱"AI+车"新启 程》 2025-05-18 核心观点 盈利预测 | [币种Table_FinchinaSimple] (人民币) | 2023A | 2024A | 2025E | 2026E | ...

Investment Rating - The report assigns an "Accumulate" rating for Lenovo Group (00992) for the first time [2]. Core Views - Lenovo is the largest PC manufacturer globally, with a market share of 24.8% as of Q2 2025, and operates in 180 countries with around 80,000 employees [7][11]. - The company's revenue for Q2 2025 reached $18.83 billion, a year-on-year increase of 21.9%, exceeding Bloomberg's expectations [7]. - The adjusted net profit for Q2 2025 was $390 million, a 22% increase year-on-year, also surpassing Bloomberg's forecast [7]. - The report anticipates revenue growth driven by AI PC penetration and AI server expansion, projecting revenues of $77.38 billion, $83.68 billion, and $91.22 billion for 2025, 2026, and 2027 respectively [7][42]. Summary by Sections Company Overview - Lenovo is recognized as the largest PC manufacturer globally, with a significant global presence and a strategic focus on digital transformation [11]. - The company has a robust shareholder structure, with Lenovo Holdings being the largest shareholder [14]. IDG: AI PC Penetration - The Intelligent Devices Group (IDG) reported revenue of $13.46 billion in Q2 2025, marking a 17.8% year-on-year increase, driven by the growth of AI PCs and mobile business [21][26]. - The AI PC market is expected to grow significantly, with projections indicating a market penetration rate of 85% by 2027 [25]. SSG: Diversification Strategy - The Solutions and Services Group (SSG) achieved a revenue growth of 19.8% in Q1 FY25/26, driven by AI infrastructure and industry solutions [30]. - SSG is positioned as a leading player in the IT services market, maintaining the fastest revenue growth for eight consecutive years [27]. ISG: AI Server Growth - The Infrastructure Solutions Group (ISG) experienced a 36% year-on-year revenue increase in Q1 FY25/26, attributed to rising cloud investments and strong server demand [35]. - The company aims to become a leading provider of end-to-end infrastructure solutions, leveraging advanced technologies like liquid cooling [36]. Profit Forecast and Valuation Analysis - The report forecasts a compound annual growth rate (CAGR) of approximately 15.2% for adjusted net profit from FY24/25 to FY27/28, with projected adjusted net profits of $1.63 billion for FY25/26 [43][44]. - The report highlights a favorable valuation with a projected PE ratio of 10.7 for FY25/26, compared to an average of 19.4 for comparable companies [44].

Investment Rating - The investment rating for the company is "Accumulate" (maintained) [2] Core Views - The company reported a revenue of 5.44 billion yuan in the first half of 2025, a decrease of 15.31%, with a net profit of 5.63 billion yuan, down by 9.89% [7] - The company's CDMO business is experiencing rapid growth, with revenue increasing by 20.32% to 12.36 billion yuan, while the raw material drug business faced challenges, with revenue declining by 23.41% to 36.03 billion yuan [7] - The company is expected to achieve revenues of 10.896 billion yuan, 11.512 billion yuan, and 13.081 billion yuan for the years 2025, 2026, and 2027 respectively, with corresponding net profits of 1.028 billion yuan, 1.224 billion yuan, and 1.477 billion yuan [7] Financial Performance Summary - Revenue for 2023A was 11,474 million yuan, with a growth rate of 8.8%, while the forecast for 2025E is 10,896 million yuan, reflecting a decline of 9.4% [6][8] - The net profit for 2023A was 1,055 million yuan, with a growth rate of 6.7%, and is expected to be 1,028 million yuan in 2025E, showing a slight decline of 0.3% [6][8] - The company's gross margin for the first half of 2025 was 25.73%, an increase of 1.03 percentage points compared to the previous period [7] Business Structure and Strategy - The company has formed a "funnel" model for its CDMO project structure, with 1,180 ongoing projects, of which 377 are in the commercialization stage [7] - The company is advancing its business transformation strategy, focusing on "starting raw materials + registered intermediates + API + formulations," with a total of 134 API projects [7] - The company is accelerating its "multi-variety" strategy in the formulation business, with 68 projects under research, including a semaglutide injection that has entered phase III clinical trials [7]

Investment Rating - The investment rating for the company is "Accumulate" (maintained) [2] Core Views - The company reported a revenue of 1.249 billion yuan for 1H2025, representing a year-on-year increase of 21.81%, and a net profit attributable to shareholders of 120 million yuan, up 42.54% year-on-year [7][8] - The engineering segment saw significant revenue growth, primarily due to the steady progress of the Beifang Huajin project, which generated 239 million yuan in revenue in 1H2025 [7][8] - The company expects to achieve net profits of 339 million yuan, 451 million yuan, and 581 million yuan for the years 2025 to 2027, respectively, with corresponding PE ratios of 17.9, 13.5, and 10.5 [7][8] Financial Performance Summary - Revenue projections for the company are as follows: 2,657 million yuan in 2023, 2,554 million yuan in 2024, 3,075 million yuan in 2025, 3,658 million yuan in 2026, and 4,296 million yuan in 2027, with a revenue growth rate of 20.4% in 2025 [6][9] - The net profit attributable to shareholders is projected to be 282 million yuan in 2023, 263 million yuan in 2024, 339 million yuan in 2025, 451 million yuan in 2026, and 581 million yuan in 2027, with a net profit growth rate of 29.2% in 2025 [6][9] - The company's sales gross margin for 1H2025 was 19.94%, an increase of 0.89 percentage points year-on-year, while the net profit margin was 9.64%, up 1.4 percentage points year-on-year [7][8] Market Performance - The company's stock price closed at 9.38 yuan as of August 20, 2025, with a circulating share capital of 629 million shares and a total share capital of 649 million shares [2]

-6% 26% 58% 89% 121% 153% 盐津铺子 沪深300 上证指数 休闲食品 分析师 吴文德 SAC 证书编号：S0160523090004 wuwd01@ctsec.com 分析师 黄欣培 SAC 证书编号：S0160525070004 huangxp01@ctsec.com 魔芋高景气度持续放量，费用率实现优化 盐津铺子(002847) 证券研究报告 休闲食品 / 公司点评 / 2025.08.21 投资评级:买入(维持) | 基本数据 | 2025-08-20 | | --- | --- | | 收盘价(元) | 73.96 | | 流通股本(亿股) | 2.46 | | 每股净资产(元) | 7.98 | | 总股本(亿股) | 2.73 | 最近 12 月市场表现 相关报告 1. 《收入端高质量增长，所得税率影响利润 表现》 2024-10-31 2. 《收入端韧性突出，多品牌布局逐步完 善》 2024-08-12 3. 《收入端韧性突出，重视股东回报》 2024-07-15 核心观点 ❖ 风险提示：新品增长不及预期；原料价格波动超预期；食品安全风险 盈利预测 | [币种Table_ ...

Investment Rating - The investment rating for the company is "Buy" (maintained) [2] Core Views - The company is preparing for its H-share issuance and listing on the Hong Kong Stock Exchange, with a final price set at HKD 42.80 per share [7] - The company has established itself as a significant supplier in the semiconductor industry, ranking among the top three global manufacturers of silicon carbide (SiC) substrates, with a market share of 16.7% [7] - The demand for SiC substrates is expanding into AI server power supply units, driven by the increasing need for high-performance AI computing [7] - Revenue projections for 2025-2027 are estimated at CNY 25.38 billion, CNY 32.68 billion, and CNY 41.12 billion, with corresponding net profits of CNY 3.12 billion, CNY 5.19 billion, and CNY 8.15 billion [7] Financial Performance Summary - The company reported a revenue of CNY 1,251 million in 2023, with a projected growth rate of 199.9% [6] - The net profit is expected to turn positive in 2024, reaching CNY 179 million, and continue to grow to CNY 815 million by 2027 [6] - The earnings per share (EPS) is projected to increase from -0.11 in 2023 to 1.90 by 2027 [6] - The price-to-earnings (PE) ratio is expected to decrease from 121.9 in 2024 to 35.3 in 2027, indicating improving profitability [6] Market Performance - The company has shown a significant market performance compared to the Shanghai and Shenzhen 300 index, with a 12-month performance of 76% [4]

Investment Rating - The investment rating for the company is "Accumulate" (maintained) [2] Core Views - The company reported a significant increase in revenue and net profit for the first half of 2025, with revenue reaching 1.456 billion yuan, up 18.96% year-on-year, and net profit of 174 million yuan, up 42.30% year-on-year [8] - The second quarter of 2025 saw revenue of 692 million yuan, an increase of 7.75% year-on-year, and a net profit of 92 million yuan, up 28.42% year-on-year [8] - The company benefits from a favorable demand structure, particularly in the wind power and home appliance sectors, which has led to a good performance in production and sales [8] - The report anticipates continued growth in net profit for 2025-2027, with expected figures of 408 million yuan, 506 million yuan, and 583 million yuan respectively, representing growth rates of 49%, 24%, and 15% [8] Financial Performance Summary - Revenue for 2023 was 2.607 billion yuan, with a projected increase to 3.215 billion yuan in 2025, reflecting a growth rate of 20.80% [7] - The net profit for 2023 was 296 million yuan, with an expected increase to 408 million yuan in 2025, indicating a growth rate of 48.50% [7] - The company's earnings per share (EPS) is projected to rise from 0.72 yuan in 2023 to 1.00 yuan in 2025 [7] - The price-to-earnings (PE) ratio is expected to be 16.69 in 2025, indicating a reasonable valuation compared to historical performance [7] Market Performance - The company's stock has shown a strong performance compared to the CSI 300 index, with a notable increase of 54% over the past 12 months [4]

构建大模型全栈能力，推进 AI 产业化 大华股份(002236) 证券研究报告 计算机设备 / 公司跟踪研究报告 / 2025.08.20 | 投资评级:增持(维持) | | --- | | 基本数据 | 2025-08-19 | | --- | --- | | 收盘价(元) | 18.20 | | 流通股本(亿股) | 21.16 | | 每股净资产(元) | 11.30 | | 总股本(亿股) | 32.87 | 最近 12 月市场表现 -5% 8% 21% 34% 48% 61% 大华股份 沪深300 计算机设备 分析师 张益敏 SAC 证书编号：S0160522070002 zhangym02@ctsec.com 分析师 吴姣晨 SAC 证书编号：S0160522090001 wujc01@ctsec.com 相关报告 1. 《聚焦高质量增长，把握经济与技术的共 振机遇》 2025-08-18 2. 《业务结构分化仍存压力，AI 模型产业 化加速》 2025-03-30 3. 《化债政策有望对回款、新项目推进产生 积极影响》 2024-10-27 核心观点 ❖ 风险提示：地缘政治环境风险、全球经济下行 ...

Investment Rating - The investment rating for the company is "Accumulate" (maintained) [2] Core Views - The company has successfully promoted its products through external channels and accelerated its R&D progress [7] - The company has established a differentiated product portfolio in the hypertension field, enhancing its brand influence in chronic disease management [7] - The company is expected to achieve revenue of 44.54 billion, 53.44 billion, and 62.53 billion yuan, and net profit of 6.28 billion, 6.90 billion, and 7.96 billion yuan from 2025 to 2027, with corresponding PE ratios of 89.6, 81.6, and 70.8 [7] Financial Performance - In the first half of 2025, the company achieved revenue of 2.131 billion yuan, a year-on-year increase of 4.32%, and a net profit of 365 million yuan, a year-on-year increase of 6.10% [7] - The company’s R&D investment in the first half of 2025 was 542 million yuan, accounting for 25.43% of revenue [7] - The company’s revenue projections for 2025E, 2026E, and 2027E are 44.54 billion, 53.44 billion, and 62.53 billion yuan respectively, with net profit projections of 6.28 billion, 6.90 billion, and 7.96 billion yuan [6][7] Market Performance - The company’s stock performance over the last 12 months shows a range of fluctuations, with a maximum increase of 101% compared to the benchmark index [4]